Clinical Trial: Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults

U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935200) titled 'Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy Adults' on Oct. 28.

Brief Summary: This Phase 1 clinical trial aims to compare the pharmacokinetics and safety of UI112 and UIC202611 (Wegovy), two injectable products containing semaglutide, in healthy adult volunteers.

A total of 44 healthy adults will be randomly assigned to one of two treatment sequences. Each participant will receive a single 0.5 mg subcutaneous injection of UI112 and UIC202611 in separate treatment periods, with a 6-week washout period between administrations.

Blood samples will be collected at scheduled time points to measure semaglutid...